Cordyceps Sunshine Biotech Holdings Co., Ltd. income statement RAJAF

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Cordyceps Sunshine Biotech Holdings Co., Ltd. reported revenue of $1.2 million, down 0.6% from the year before. It recorded a net loss of $154,822. The operating loss came to $141,128, an operating margin of -11.3%. Diluted earnings per share were $0.00. Across the 4 fiscal years shown, revenue grew from $53,304 in fiscal 2022 to $1.2 million in fiscal 2025, about 185.9% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022
Revenue	1 -0.6%	1 +42.0%	1 +1555.7%	0
Cost of revenue	0 +39.7%	0 +198.8%	0 +744.9%	0
Gross profit	1 -16.1%	1 +18.3%	1 +1837.4%	0
Research and development	—	—	—	0
Selling, general and administrative	—	—	1 +58.5%	0
Operating income	-0 +23.3%	-0 -180.7%	0 +154.9%	-0
Other income (expense)	-0 -85.4%	-0 +80.0%	-0 -370280.0%	0
Pretax income	-0 +19.1%	-0 -200.3%	0	—
Income tax	—	0 +62.4%	0 +2618.4%	0
Net income	-0 +31.6%	-0 -130.1%	1 +204.4%	-1
Basic EPS	0.00	0.00 -100.0%	0.01 +200.0%	-0.01
Diluted EPS	0.00	0.00 -100.0%	0.01 +200.0%	-0.01
Weighted average shares, basic	111 +0.0%	111 +0.0%	111 +6.4%	104
Weighted average shares, diluted	111 +0.0%	111 +0.0%	111 +6.4%	104
Other measures
Depreciation and amortization	0 -66.8%	0 +617.6%	0 +131.8%	0
EBITDA	-0 -102.6%	0 -21.5%	0 +172.9%	-0
Interest coverage	—	—	8.59x	-5.78x
Margins
Gross margin	61.09%	72.32%	86.84%	74.21%
Operating margin	-11.33%	-14.67%	25.82%	-778.78%
Pretax margin	-12.43%	-15.26%	21.62%	—
Profit margin	-12.43%	-18.05%	85.16%	-1,350.92%
EBITDA margin	-0.47%	17.82%	32.25%	-732.84%
Effective tax rate	—	—	11.28%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as: RAJAF (OTC)
Fiscal year ends: December 31
Headquarters: Taipei City
SEC filer status: Non-accelerated filer, Emerging growth company
SEC CIK: 1885680
Former names: Cordyceps Sunshine Biotech Holdings Co., Ltd. (until Jun 25, 2026)

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.